{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":4686,"total_is_capped":false,"direct_labels_cover":13,"predictions_cover":4686,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"d0c1ba793e2a","filters":{"topic":"Multiple Sclerosis Research Studies"}},"results":[{"id":"W2122545833","doi":"10.1002/ana.22366","title":"Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria","year":2011,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9828,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Multiple sclerosis; McDonald criteria; Medicine; Space (punctuation); Diagnostic test; Medical physics; Computer science; Intensive care medicine; Pediatrics; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.418695174841573,"gpt":0.4210162387167591,"spread":0.002321063875186102,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.000655041,0.0001919792,0.0004920776,0.0001603121,0.0001707412,0.00001158229,0.0003541297,0.0001028909,0.0005621425],"category_scores_gemma":[0.01398691,0.0001307364,0.0002045188,0.0002065583,0.0002535351,0.0000645947,0.0002889191,0.000228338,0.00008991702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003244893,"about_ca_system_score_gemma":0.00003851231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000157827,"about_ca_topic_score_gemma":0.00008532903,"domain_scores_codex":[0.9981265,0.0002109801,0.0004419401,0.0004098705,0.0002411513,0.0005695347],"domain_scores_gemma":[0.9959282,0.002489741,0.0001017832,0.0006771898,0.0005697274,0.0002333292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.003335186,0.0007431292,0.0221179,0.0002779851,0.0002459575,0.00002983842,0.001825101,0.000003390826,0.08739235,0.0001803032,0.8686652,0.01518363],"study_design_scores_gemma":[0.000956952,0.002926128,0.9138023,0.0001274617,0.00005171647,0.00001442569,0.00004218312,0.0002419488,0.008866083,0.0001566135,0.07268903,0.0001251617],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8573757,0.001056159,0.0003702547,0.1365206,0.0008431358,0.00260156,0.0003045287,0.00007047648,0.0008575707],"genre_scores_gemma":[0.9786569,0.001719387,0.001088153,0.01752068,0.0003337868,0.0005076927,0.00001331065,0.00003560333,0.0001245268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8916844,"threshold_uncertainty_score":0.9943187,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2777074421","doi":"10.1016/s1474-4422(17)30470-2","title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","year":2017,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7986,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; University of Toronto; St. Michael's Hospital; University of Manitoba; Ottawa Hospital; University of Ottawa","funders":"National Multiple Sclerosis Society","keywords":"Multiple sclerosis; McDonald criteria; Medicine; Clinically isolated syndrome; Clinical Practice; Presentation (obstetrics); Medical physics; Neuroscience; Pathology; Radiology; Psychology; Physical therapy; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.4832657941316096,"gpt":0.4610466501040005,"spread":0.02221914402760911,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001077374,0.0003911635,0.00380126,0.0001220806,0.000306604,0.00001678638,0.001973861,0.0002965665,0.0001347581],"category_scores_gemma":[0.007240262,0.0001815001,0.0009240565,0.0001997124,0.001381213,0.00003568593,0.001348673,0.001147155,0.00003627337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001931783,"about_ca_system_score_gemma":0.0002073012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009652533,"about_ca_topic_score_gemma":0.00005885185,"domain_scores_codex":[0.996664,0.0009789368,0.0008620979,0.0004634786,0.00049243,0.0005390171],"domain_scores_gemma":[0.9923728,0.002823729,0.001174383,0.003321862,0.0002221698,0.00008511468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002018049,0.0002009034,0.003709015,0.01861195,0.0006851916,0.00001245979,0.0001060288,4.699135e-7,0.0001083518,0.00004910998,0.1040942,0.8722205],"study_design_scores_gemma":[0.0007313297,0.0001976399,0.05123073,0.0119273,0.0008234382,0.00003695077,0.000002590247,0.000006121471,0.00003518445,0.00001551728,0.9348744,0.0001187939],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006352069,0.9870549,6.047802e-7,0.008091613,0.0005395609,0.001860737,0.0004429758,0.00002389324,0.001350521],"genre_scores_gemma":[0.006577873,0.9914154,0.00003921649,0.0005381895,0.000722474,0.0004825101,0.00001740186,0.00005238199,0.0001544987],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8721017,"threshold_uncertainty_score":0.8667793,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105490558","doi":"10.1002/ana.1032","title":"Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis","year":2001,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6953,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Multiple Sclerosis Society","keywords":"Multiple sclerosis; Medicine; Magnetic resonance imaging; Disease; McDonald criteria; Diagnostic test; Pediatrics; Radiology; Pathology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.5788509391261998,"gpt":0.4242108626109629,"spread":0.1546400765152369,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009334678,0.0002730699,0.000600366,0.0001313081,0.000194129,0.00002411574,0.0007424718,0.0001356826,0.0003532989],"category_scores_gemma":[0.04446394,0.0001633523,0.0003483601,0.0002236597,0.0003620317,0.00007625831,0.0003280879,0.0003020989,0.00001670002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001115348,"about_ca_system_score_gemma":0.0000441378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008418924,"about_ca_topic_score_gemma":0.0003788221,"domain_scores_codex":[0.997324,0.0003285743,0.0008580196,0.0004851808,0.0005233766,0.0004808801],"domain_scores_gemma":[0.9720748,0.02562164,0.0003522564,0.0007440639,0.001101932,0.0001053221],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004084215,0.001105212,0.5120919,0.0000457682,0.0007651658,0.000008476843,0.0005354088,0.00009119742,0.03763831,0.00009252482,0.4125649,0.03097692],"study_design_scores_gemma":[0.003212153,0.001499912,0.9113569,0.0003729323,0.00008626928,0.000004279052,0.0002179692,0.003815442,0.03427465,0.0004165909,0.04457869,0.0001641963],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7415881,0.0005042252,0.00004685047,0.255682,0.0004397262,0.001005817,0.0005927237,0.00002959608,0.0001109488],"genre_scores_gemma":[0.9563901,0.01698471,0.0003399376,0.02465746,0.0005757803,0.0008965672,0.0000778845,0.00004088627,0.00003668237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3992651,"threshold_uncertainty_score":0.963585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2916040650","doi":"10.1002/ana.20703","title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”","year":2005,"lang":"en","type":"review","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Foothills Medical Centre","funders":"Multiple Sclerosis Society","keywords":"Multiple sclerosis; Medicine; McDonald criteria; Magnetic resonance imaging; Diagnostic test; Diagnostic accuracy; Disease; Spinal cord; Radiology; Pediatrics; Pathology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.4522226167627964,"gpt":0.4959783973921078,"spread":0.04375578062931135,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001262214,0.00060706,0.002957334,0.0004421451,0.0002317977,0.00003758341,0.0007814008,0.0003842125,0.0005170085],"category_scores_gemma":[0.02269123,0.0003897138,0.001105042,0.000407539,0.0003018955,0.00006573391,0.0005847355,0.0006860986,0.0002168842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001925851,"about_ca_system_score_gemma":0.0002291255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003002656,"about_ca_topic_score_gemma":0.00007559791,"domain_scores_codex":[0.9955461,0.000701973,0.001296097,0.0008869009,0.0004701663,0.001098779],"domain_scores_gemma":[0.9875112,0.009816125,0.0003989032,0.001277347,0.0005877865,0.0004086052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001865419,0.0002038542,0.00001206917,0.005038847,0.0002773375,0.0000119546,0.00004780526,0.000001548585,0.00003074972,0.00001360936,0.3944984,0.5996773],"study_design_scores_gemma":[0.0005856708,0.001236291,0.001975643,0.006742341,0.0005184563,0.00004643526,0.000005244849,0.00004270776,0.000008574689,0.000008033856,0.9885746,0.0002560093],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007785398,0.9389023,0.00004147465,0.05423763,0.0004626495,0.00498432,0.001075279,0.00005208077,0.0001664658],"genre_scores_gemma":[0.0004431585,0.9840382,0.0004381729,0.0103501,0.001902516,0.002310966,0.0001474049,0.0001228776,0.0002466148],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5994213,"threshold_uncertainty_score":0.9998555,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129229339","doi":"10.1212/wnl.0000000000001729","title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","year":2015,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4543,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Chugai Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; National Eye Institute; Astellas Pharma; Novartis Pharma; Ministry of Education, Science and Technology; Multiple Sclerosis Society of Canada; European Committee for Treatment and Research in Multiple Sclerosis; Alexion Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Teijin Pharma; Teva Pharmaceutical Industries; Acorda Therapeutics; Viropharma; GlaxoSmithKline; Biogen; Ono Pharmaceutical; Eisai; National Institutes of Health; Guthy-Jackson Charitable Foundation; Daiichi Sankyo Europe; Sanofi","keywords":"Neuromyelitis optica; Medicine; Multiple sclerosis; Neuroimaging; Consensus conference; Spinal cord; Serology; Pathology; Optic neuritis; Spectrum disorder; Aquaporin 4; Antibody; Immunology; Internal medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.0706054789918104,"gpt":0.3591950605308502,"spread":0.2885895815390397,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001577871,0.0001254429,0.0002406471,0.0001086017,0.00004781975,0.00001568601,0.0001282282,0.00006447083,0.0001638479],"category_scores_gemma":[0.007404708,0.0001107802,0.00007257962,0.00006538165,0.000235547,0.00002230285,0.0001257073,0.0001890771,0.0000627749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002123701,"about_ca_system_score_gemma":0.0000649768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000751077,"about_ca_topic_score_gemma":0.00007296655,"domain_scores_codex":[0.9988225,0.00008352046,0.00019266,0.0003172553,0.0002192469,0.0003648908],"domain_scores_gemma":[0.9979563,0.001483443,0.00003620789,0.0002135259,0.0001072339,0.0002033148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01959718,0.001843384,0.3514203,0.0003536372,0.001000046,0.001332872,0.001717519,0.0002274653,0.01883067,0.008649049,0.5423963,0.0526316],"study_design_scores_gemma":[0.006907232,0.005276054,0.3932724,0.00001298614,0.00005223714,0.0002321736,0.00002840958,0.005680108,0.0002288852,0.002378901,0.5857467,0.0001839337],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.677447,0.0001085441,0.0003922059,0.3034953,0.002168791,0.0009989295,0.00008644989,0.0001203477,0.01518235],"genre_scores_gemma":[0.9956958,0.000280553,0.0008818592,0.002181008,0.0005963986,0.0001471676,0.00003009222,0.00002675483,0.0001603088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3182488,"threshold_uncertainty_score":0.8864662,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105206040","doi":"10.1212/wnl.0000000000000560","title":"Defining the clinical course of multiple sclerosis","year":2014,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3133,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; EMD Serono; Acorda Therapeutics; University of Cambridge; Bayer Canada; National Institutes of Health; Multiple Sclerosis Society; Schweizerische Multiple Sklerose Gesellschaft; Eisai; National Institute for Health and Care Research; National Research Foundation; Wolfson Foundation; Genentech; European Commission; Glenmark Pharmaceuticals; Multiple Sclerosis International Federation; Sanofi; GW Pharmaceuticals; Alexion Pharmaceuticals; Myelin Repair Foundation; Bayer HealthCare; Grifols; F. Hoffmann-La Roche; Ironwood Pharmaceuticals, Incorporated; Eli Lilly and Company; University of Alabama; Wellcome Trust; European Committee for Treatment and Research in Multiple Sclerosis; Sanofi Genzyme; University of Alabama at Birmingham; Medical Research Council; Teva Pharmaceutical Industries; Gilead Sciences; GlaxoSmithKline; University of Texas Health Science Center at Houston; Celgene; Natural Sciences and Engineering Research Council of Canada; Pfizer; Biogen; Serono Symposia International Foundation; Novartis Pharmaceuticals Corporation; National Multiple Sclerosis Society; National Heart, Lung, and Blood Institute; Sun Pharma; Cleveland Clinic; Canadian Institutes of Health Research; Prothena; Amylin Pharmaceuticals","keywords":"Multiple sclerosis; Clinical trial; Clinical phenotype; Disease; Medicine; Clinical disease; Phenotype; Medical physics; Pathology; Intensive care medicine; Bioinformatics; Biology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.1177601972499049,"gpt":0.3778439076248274,"spread":0.2600837103749226,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009791456,0.00009884452,0.0003826547,0.00003931649,0.00008907908,0.000003972253,0.0001684911,0.0001027563,0.0000538804],"category_scores_gemma":[0.003796578,0.00005933504,0.0001380542,0.0001119569,0.0006124122,0.00001686592,0.0001676066,0.0004497533,0.00006602936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003295379,"about_ca_system_score_gemma":0.00004415064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006554893,"about_ca_topic_score_gemma":0.00008804482,"domain_scores_codex":[0.9984798,0.0004209366,0.000359466,0.0002456002,0.0002072351,0.0002869738],"domain_scores_gemma":[0.9961237,0.00308917,0.0001029841,0.0004647874,0.0001261448,0.00009315808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007025123,0.0002311391,0.9230911,0.00002446843,0.00009147363,0.000002815389,0.0001119947,0.0000133897,0.00309924,0.0006121789,0.005045592,0.06697407],"study_design_scores_gemma":[0.001750613,0.001540749,0.9748701,0.00001273981,0.00003501578,0.000009277064,0.00001300341,0.002790276,0.0006444684,0.00002977399,0.01826177,0.00004220559],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862103,0.0002808012,0.0001008575,0.01072553,0.0002661693,0.0002374777,0.000006214169,0.00003793009,0.002134738],"genre_scores_gemma":[0.9958904,0.0003483686,0.0002485017,0.003265099,0.0001820464,0.00002228011,0.000003052547,0.00001568613,0.00002461518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06693186,"threshold_uncertainty_score":0.4545132,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3099273656","doi":"10.1177/1352458520970841","title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","year":2020,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2525,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"Biogen; Novartis; Multiple Sclerosis Society; Roche; Medical Research Council; Associazione Italiana Sclerosi Multipla; Sanofi; Merck; Bristol-Myers Squibb; University of Tasmania; National Multiple Sclerosis Society","keywords":"Multiple sclerosis; Medicine; Epidemiology; Incidence (geometry); Compendium; Environmental health; Population; Demography; Gerontology; Geography; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1256524917755574,"gpt":0.2900817352026255,"spread":0.1644292434270681,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007875158,0.0005045192,0.001138461,0.0002314011,0.0006575694,0.0001158348,0.0008521554,0.0002147529,0.0004170454],"category_scores_gemma":[0.007283611,0.0003494418,0.0006712191,0.0009701706,0.0007743884,0.0005493232,0.0004806652,0.001358174,0.00005822826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001879889,"about_ca_system_score_gemma":0.0002443551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005828926,"about_ca_topic_score_gemma":0.0001715649,"domain_scores_codex":[0.9942762,0.0005690844,0.001676242,0.0006664555,0.002105197,0.0007068192],"domain_scores_gemma":[0.9937534,0.002603083,0.001085618,0.0007464428,0.001167148,0.0006443209],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001134278,0.0004191312,0.3097609,0.0003885635,0.0005302308,0.000008032755,0.004515795,0.000293469,0.6604061,0.000008780836,0.01354218,0.008992541],"study_design_scores_gemma":[0.005628736,0.0004601819,0.8163942,0.002843515,0.0002957348,0.000008791696,0.0009101983,0.005885793,0.1661421,0.00003549689,0.001109481,0.0002857193],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864407,0.004659822,0.001607917,0.005000722,0.0005162474,0.001036751,0.0003999193,0.00008636324,0.0002515306],"genre_scores_gemma":[0.9844695,0.00806657,0.005031165,0.0005601616,0.001683213,0.00004054983,0.00003462763,0.00007451793,0.00003964971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5066333,"threshold_uncertainty_score":0.9998958,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141111992","doi":"10.1056/nejmoa0706383","title":"B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis","year":2008,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2399,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"GlaxoSmithKline; Biogen; Eisai; Sanofi; Teva Pharmaceutical Industries; Genentech; AstraZeneca","keywords":"Medicine; Rituximab; Placebo; Multiple sclerosis; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; CD20; Magnetic resonance imaging; Relapsing remitting; Surgery; Clinical trial; Immunology; Pathology; Lymphoma; Radiology","retraction":null,"screen_n_in":null,"score":{"opus":0.07419576150057383,"gpt":0.2794389112804177,"spread":0.2052431497798439,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001295122,0.0002022061,0.0007809822,0.0004815208,0.0001198713,0.000006240879,0.000128683,0.0000753247,0.00008050192],"category_scores_gemma":[0.002312534,0.0001226397,0.00007539213,0.0004581076,0.0002583088,0.0001467817,0.0000349714,0.0008026547,0.000006883949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001573151,"about_ca_system_score_gemma":0.000260379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003932655,"about_ca_topic_score_gemma":0.0001507952,"domain_scores_codex":[0.9974954,0.0001342384,0.0007268351,0.000199416,0.001067935,0.0003762144],"domain_scores_gemma":[0.9980406,0.0006175039,0.0003496289,0.0002010745,0.0003947536,0.0003964474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006136277,0.001015849,0.8252189,0.0001876852,0.000161967,0.001379779,0.006751863,0.0001322822,0.05430663,0.000004875489,0.02953725,0.07516664],"study_design_scores_gemma":[0.367326,0.00441895,0.5994575,0.005104018,0.000155769,0.003514167,0.001060949,0.0005205048,0.003125413,0.00002224626,0.01506303,0.0002314177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850211,0.003563773,0.0008984305,0.008069482,0.0002039119,0.0002551466,8.148176e-7,0.00001991967,0.001967414],"genre_scores_gemma":[0.9869658,0.005079577,0.005138956,0.0002853873,0.002050259,0.000002741391,0.000003609071,0.00002911901,0.0004446003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3611898,"threshold_uncertainty_score":0.50011,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2561881161","doi":"10.1056/nejmoa1601277","title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1961,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NeuroRx Research (Canada); McGill University; University of British Columbia","funders":"Agence Nationale de la Recherche","keywords":"Ocrelizumab; Medicine; Interferon beta-1a; Multiple sclerosis; Hazard ratio; Internal medicine; Confidence interval; Gastroenterology; Immunology; Interferon beta; Rituximab","retraction":null,"screen_n_in":null,"score":{"opus":0.1261491570014691,"gpt":0.3314055627944734,"spread":0.2052564057930043,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001514334,0.0002261512,0.0008307325,0.0005692253,0.00005755034,0.000009571893,0.0002065638,0.00009208339,0.0004544729],"category_scores_gemma":[0.005122514,0.0001160379,0.0001280605,0.000306711,0.0002597239,0.0001929167,0.00008337112,0.0005419498,0.00001980771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003541348,"about_ca_system_score_gemma":0.0001952184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001729007,"about_ca_topic_score_gemma":0.000261628,"domain_scores_codex":[0.9973187,0.0001720043,0.0008951667,0.0002238411,0.0009458008,0.0004444416],"domain_scores_gemma":[0.996952,0.001632896,0.00031294,0.0002758349,0.0003328609,0.0004934925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02915732,0.0001765027,0.04383821,0.00007048127,0.0003375103,0.0003274014,0.001888876,0.000007018991,0.1564684,0.00003304296,0.03397592,0.7337193],"study_design_scores_gemma":[0.6362509,0.01827127,0.2181388,0.01733402,0.000338148,0.0005827502,0.001168432,0.0001294497,0.008487961,0.0001604242,0.09874581,0.0003920747],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9360158,0.00426883,0.001108756,0.05341542,0.001707445,0.0003068278,0.000004062055,0.00002765566,0.003145227],"genre_scores_gemma":[0.9889429,0.006130571,0.0008818333,0.0001615029,0.003214867,0.000002742631,0.000001660812,0.00002942723,0.0006345373],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7333272,"threshold_uncertainty_score":0.6132498,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2093009907","doi":"10.1056/nejmoa1114287","title":"Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1703,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Placebo; Medicine; Multiple sclerosis; Internal medicine; Clinical endpoint; Regimen; Placebo-controlled study; Gastroenterology; Randomized controlled trial; Double blind; Immunology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1492640750751503,"gpt":0.3816020995237962,"spread":0.2323380244486459,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004375723,0.0002531897,0.001668978,0.0004528604,0.0001229286,0.000008114292,0.0001727594,0.00007582409,0.0001513211],"category_scores_gemma":[0.008774925,0.0001502455,0.0002225617,0.0002156899,0.0001525204,0.0002021294,0.00004985396,0.0004502641,0.00000173118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009973476,"about_ca_system_score_gemma":0.0001421173,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001546962,"about_ca_topic_score_gemma":0.00009562138,"domain_scores_codex":[0.9966842,0.000260713,0.00125968,0.0001630311,0.00111504,0.0005173562],"domain_scores_gemma":[0.9957575,0.001908046,0.0007311373,0.000269467,0.0006451426,0.0006887533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2139076,0.007789485,0.1836329,0.0003432075,0.003447513,0.00005504095,0.02306958,0.00005375879,0.1639348,0.00001854679,0.04549734,0.3582503],"study_design_scores_gemma":[0.9316927,0.01725197,0.0286666,0.001194058,0.001369901,0.0001333191,0.004879729,0.0006029509,0.001500446,0.00001660498,0.01253786,0.0001539062],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894096,0.002606981,0.00153655,0.003146698,0.0009198256,0.001911714,0.000006327127,0.00001660719,0.0004456584],"genre_scores_gemma":[0.9924852,0.0005669551,0.002311771,0.000108609,0.004015124,0.00002521392,0.000004567059,0.00003519644,0.000447312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7177851,"threshold_uncertainty_score":0.9995746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2313649737","doi":"10.1056/nejm200009283431301","title":"Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis","year":2000,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1509,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Victoria General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Multiple sclerosis; Interferon beta-1a; Placebo; Clinically isolated syndrome; Internal medicine; Gastroenterology; Interferon beta-1b; Magnetic resonance imaging; Surgery; Pathology; Immunology; Radiology; Interferon beta","retraction":null,"screen_n_in":null,"score":{"opus":0.1111449058913719,"gpt":0.3227929115631566,"spread":0.2116480056717847,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001662442,0.0002709728,0.0008999406,0.0005064347,0.0001283558,0.00001642372,0.0002144838,0.00009787185,0.001240417],"category_scores_gemma":[0.001295912,0.0001778729,0.0001579261,0.0004647329,0.0001681627,0.0001653632,0.00004256113,0.0008850425,0.00001024157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002227211,"about_ca_system_score_gemma":0.000116462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003997809,"about_ca_topic_score_gemma":0.0003683546,"domain_scores_codex":[0.9970017,0.0002193152,0.001126605,0.00024084,0.0009324662,0.0004790431],"domain_scores_gemma":[0.9982737,0.0005301279,0.0002651637,0.0002318222,0.0002702688,0.0004288857],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01044823,0.0005482145,0.1083528,0.0002252514,0.0006287348,0.0006441735,0.01003737,0.0008012684,0.05551917,0.000002505524,0.001833952,0.8109583],"study_design_scores_gemma":[0.1867836,0.005182426,0.7782899,0.007467817,0.00012081,0.000578594,0.000834188,0.001330827,0.006238696,0.00003592837,0.01285623,0.0002809858],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981675,0.004615083,0.00007809961,0.01266328,0.0001605035,0.0003798708,0.000002004584,0.00002338606,0.0004027642],"genre_scores_gemma":[0.9791066,0.01768557,0.0004498979,0.0002901346,0.002261283,0.000008692399,0.000005595731,0.0000350272,0.0001571906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8106773,"threshold_uncertainty_score":0.9996726,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135403800","doi":"10.1038/ng.2770","title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","year":2013,"lang":"en","type":"article","venue":"Nature Genetics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1442,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University and Génome Québec Innovation Centre; McGill University","funders":"National Center for Research Resources; National Cancer Institute; National Institute of Allergy and Infectious Diseases; Medical Research Council; National Institutes of Health; National Institute of Environmental Health Sciences; Institut National de la Santé et de la Recherche Médicale; Karolinska Institutet; Hjärt-Lungfonden; Vetenskapsrådet; Crohn's and Colitis UK; Wellcome Trust; Infrastructures en Biologie Santé et Agronomie; Multiple Sclerosis Society; Knut och Alice Wallenbergs Stiftelse; Stockholms Läns Landsting; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Institute for Health and Care Research","keywords":"Multiple sclerosis; Genome-wide association study; Biology; Genotyping; Genetics; Major histocompatibility complex; Genetic association; 1000 Genomes Project; Single-nucleotide polymorphism; Computational biology; Genotype; Immune system; Gene; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.04379249974018419,"gpt":0.3179377165219832,"spread":0.274145216781799,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004763549,0.0002511856,0.0008308768,0.0004240729,0.0001279981,0.0000430814,0.0002900217,0.0004955219,0.000684401],"category_scores_gemma":[0.002586494,0.0002101519,0.0006130976,0.001313718,0.0002140246,0.00007623467,0.0001922361,0.0005126231,0.00003918788],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009534417,"about_ca_system_score_gemma":0.0001322695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005285667,"about_ca_topic_score_gemma":0.0005198686,"domain_scores_codex":[0.9975145,0.00007096957,0.0007668892,0.000511436,0.0006509329,0.0004853071],"domain_scores_gemma":[0.9971552,0.0003799409,0.0002347325,0.0008802164,0.001111033,0.0002388288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0002264348,0.0004061538,0.4609456,0.0003125253,0.006436896,0.000001068103,0.0009893866,0.0003239136,0.4849629,0.00001224804,0.0214642,0.02391867],"study_design_scores_gemma":[0.002160471,0.0001395135,0.9464592,0.00005664574,0.001415407,4.800991e-7,0.0002248578,0.0127545,0.03597514,0.0001099566,0.0005301398,0.0001736579],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904771,0.005846593,0.000582491,0.0007346884,0.000284465,0.001678083,0.0001340394,0.00005798184,0.0002045517],"genre_scores_gemma":[0.9905564,0.001167379,0.00624892,0.00009600163,0.0001082697,0.00006374253,0.0001992775,0.00003389276,0.001526144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4855137,"threshold_uncertainty_score":0.8569745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106467284","doi":"10.1056/nejmoa020696","title":"A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis","year":2003,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1245,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Multiple Sclerosis Society","keywords":"Natalizumab; Medicine; Multiple sclerosis; Kilogram; Placebo; Gastroenterology; Internal medicine; Randomized controlled trial; Surgery; Urology; Immunology; Pathology; Body weight","retraction":null,"screen_n_in":null,"score":{"opus":0.09725850463914495,"gpt":0.337780820711581,"spread":0.240522316072436,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003056489,0.000188388,0.00148979,0.0003576654,0.00008078786,0.000006707535,0.00012392,0.00008378972,0.0001309582],"category_scores_gemma":[0.02722592,0.0001122317,0.0003170401,0.0002250313,0.0002012134,0.00008233561,0.00001734579,0.0003337363,8.624502e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008286261,"about_ca_system_score_gemma":0.0003823536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004157022,"about_ca_topic_score_gemma":0.0000195262,"domain_scores_codex":[0.9971831,0.0002128958,0.00119058,0.0001552652,0.0009467071,0.0003113928],"domain_scores_gemma":[0.9955255,0.002362104,0.0006899419,0.0002201014,0.0008328109,0.0003695753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7966794,0.0006428213,0.001935487,0.0002710882,0.001286899,0.00005069162,0.001772277,0.00002623872,0.07841391,0.0003162853,0.02903046,0.08957447],"study_design_scores_gemma":[0.9521505,0.008949249,0.0007327534,0.001356873,0.0004499572,0.0001682597,0.0003570548,0.0001587416,0.003119521,0.0002090826,0.03226071,0.00008734634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9548214,0.009879752,0.008629164,0.01303887,0.003152373,0.004811894,0.00001446583,0.00002785393,0.005624208],"genre_scores_gemma":[0.9899752,0.001940052,0.004451773,0.0001374238,0.002755013,0.00002085408,0.00000320501,0.00002589761,0.0006906333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1554711,"threshold_uncertainty_score":0.9809682,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2148766438","doi":"10.1016/s0140-6736(12)61769-3","title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1198,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital; McGill University","funders":"National Institute for Health and Care Research","keywords":"Alemtuzumab; Medicine; Interferon beta-1a; Multiple sclerosis; Internal medicine; CD52; Clinical endpoint; Randomized controlled trial; Gastroenterology; Interferon beta; Immunology; Transplantation","retraction":null,"screen_n_in":null,"score":{"opus":0.1458615041298442,"gpt":0.3623954771154779,"spread":0.2165339729856337,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009580334,0.0003379982,0.001418846,0.0000747981,0.0003977395,0.00004764436,0.0002047009,0.00007792483,0.00007038508],"category_scores_gemma":[0.003145273,0.0001706856,0.0003005666,0.0001275033,0.0001512762,0.0001284193,0.00007674737,0.0002031329,0.00003017674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003496398,"about_ca_system_score_gemma":0.00007262715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008828156,"about_ca_topic_score_gemma":0.00007574682,"domain_scores_codex":[0.9976684,0.0001925767,0.0005013358,0.0003163931,0.0004820296,0.0008392415],"domain_scores_gemma":[0.9955253,0.003112229,0.0002662381,0.0006524246,0.0002249851,0.0002188027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9778662,0.002197932,0.003385344,0.00005640354,0.001412833,7.02445e-7,0.001380863,0.00001077813,0.0003822821,0.000008050482,0.002167691,0.01113088],"study_design_scores_gemma":[0.9739702,0.01624873,0.002415878,0.0003667811,0.0007269853,7.162824e-7,0.000188902,0.001006411,0.0007788583,0.000002717134,0.004108381,0.0001853815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845583,0.0007292966,0.0001754717,0.002322233,0.0006195116,0.01067746,0.0001166417,0.0001068071,0.0006942482],"genre_scores_gemma":[0.9930016,0.0004479358,0.0006578602,0.0001427783,0.002553041,0.002735011,0.0001327699,0.00005269516,0.0002763005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0140508,"threshold_uncertainty_score":0.6960355,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158202057","doi":"10.1016/s0140-6736(12)61768-1","title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1193,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital; NeuroRx Research (Canada)","funders":"National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Alemtuzumab; Multiple sclerosis; Medicine; Randomized controlled trial; Disease; Internal medicine; Physical therapy; Oncology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.1151705557353955,"gpt":0.3443890657103396,"spread":0.2292185099749441,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001012793,0.000248509,0.001015036,0.00006591964,0.0003032903,0.00005522867,0.0001664705,0.00004662399,0.00007992904],"category_scores_gemma":[0.002180676,0.0001220393,0.0002711577,0.0001235679,0.0001585123,0.0001625524,0.00005412757,0.0001995035,0.00001187746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009148143,"about_ca_system_score_gemma":0.00006262715,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001165697,"about_ca_topic_score_gemma":0.000003990057,"domain_scores_codex":[0.9978833,0.0002242299,0.0003403091,0.000250807,0.0005372191,0.0007641432],"domain_scores_gemma":[0.9972981,0.001493471,0.0001514272,0.0005909508,0.0002018437,0.0002642477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950373,0.001186254,0.03727902,0.0000649624,0.0005327016,8.684243e-7,0.0007655967,0.000002307752,0.0006985621,0.000003901734,0.002183079,0.006909754],"study_design_scores_gemma":[0.9068804,0.0008407137,0.08787069,0.0002317088,0.0002377343,2.324933e-7,0.00005267635,0.0007907822,0.0001111414,0.000007910922,0.002815892,0.0001601218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9848204,0.001920831,0.0003776909,0.001513079,0.000247279,0.01073151,0.0001477261,0.00008422504,0.0001572541],"genre_scores_gemma":[0.9911917,0.000455909,0.000760975,0.0006118326,0.002063741,0.004702941,0.00005475986,0.00005081087,0.0001073328],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05059168,"threshold_uncertainty_score":0.4976619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2025358672","doi":"10.1177/1352458513484547","title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","year":2013,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1113,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Multiple sclerosis; Medicine; Acute disseminated encephalomyelitis; Neuromyelitis optica; Demyelinating Disorder; Pediatrics; Clinically isolated syndrome; Encephalomyelitis; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.122814336372852,"gpt":0.3067056860104898,"spread":0.1838913496376378,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","sts","scholarly_communication"],"consensus_categories":[],"category_scores_codex":[0.002996704,0.001126539,0.001514417,0.001368168,0.003757594,0.001421659,0.001333973,0.0003620776,0.0004386463],"category_scores_gemma":[0.01358694,0.0008711377,0.0008758031,0.001715256,0.0002672878,0.001135143,0.001157028,0.001605287,0.0002575119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008357102,"about_ca_system_score_gemma":0.0002160066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189604,"about_ca_topic_score_gemma":0.0005411443,"domain_scores_codex":[0.9903257,0.0008915942,0.002714064,0.00149497,0.0021476,0.002425997],"domain_scores_gemma":[0.989369,0.004926842,0.001008818,0.001103117,0.001927519,0.001664689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008114454,0.002918075,0.9167821,0.0005197688,0.0008404903,0.00001065444,0.003721733,0.0003968654,0.01978664,0.00001368806,0.02087918,0.03331934],"study_design_scores_gemma":[0.01370278,0.001109155,0.9467852,0.0007592841,0.0006871726,0.00005068872,0.009051209,0.02604838,0.00008748233,0.00001159829,0.0008414194,0.0008656873],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731572,0.002621015,0.004901935,0.005495604,0.002748262,0.009495419,0.001014105,0.0004096259,0.0001568194],"genre_scores_gemma":[0.9669122,0.01172019,0.01311692,0.0003843094,0.004452306,0.002910581,0.0002057944,0.0002498299,0.00004782487],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03245366,"threshold_uncertainty_score":0.999615,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2911658427","doi":"10.1212/wnl.0000000000007035","title":"The prevalence of MS in the United States","year":2019,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1103,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Multiple Sclerosis Society","keywords":"Environmental health; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04156960221921289,"gpt":0.3266703768370823,"spread":0.2851007746178694,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003839731,0.00004560495,0.0001022641,0.00005361237,0.0000300989,0.000002921945,0.0001828447,0.00002689389,0.00006106546],"category_scores_gemma":[0.0004259317,0.00002090023,0.00002170335,0.0001889424,0.0001943539,0.00001021238,0.00006725402,0.0002348042,0.0000305877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003278119,"about_ca_system_score_gemma":0.00001569077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002346214,"about_ca_topic_score_gemma":0.00007746553,"domain_scores_codex":[0.9991828,0.0002395866,0.0001187486,0.000104577,0.0001756644,0.0001786571],"domain_scores_gemma":[0.998311,0.001289939,0.00003165303,0.0002978851,0.0000547194,0.0000148431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009326655,0.000105291,0.98616,0.0002542596,0.00002792239,0.00001478307,0.001554819,0.00009521045,0.006264617,0.0004157929,0.002470241,0.001704443],"study_design_scores_gemma":[0.0005242166,0.0008557141,0.968244,0.000007438279,0.000005599935,0.000006550433,0.00004780909,0.001216304,0.0001610116,0.00005765357,0.02885712,0.00001663998],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828871,0.0001828478,7.385474e-7,0.01538934,0.00005569074,0.0003538896,0.00000330119,0.000006295925,0.001120748],"genre_scores_gemma":[0.9956658,0.002198789,0.000003944005,0.00185353,0.00001836702,0.00001992315,0.000002023658,0.000004152752,0.0002334819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02638688,"threshold_uncertainty_score":0.102012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139204856","doi":"10.1056/nejmoa0902533","title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","year":2010,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1007,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"UCB Pharma; EMD Serono; Genentech; Multiple Sclerosis Society of Canada; Sanofi; Bayer HealthCare; Vertex Pharmaceuticals; Teva Pharmaceutical Industries; Acorda Therapeutics; Ironwood Pharmaceuticals, Incorporated; Biogen; Pfizer","keywords":"Cladribine; Medicine; Multiple sclerosis; Placebo; Relapsing remitting; Oral administration; Clinical trial; Internal medicine; Oncology; Immunology; Pathology; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08532440594402674,"gpt":0.3402950320820509,"spread":0.2549706261380242,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003772823,0.0002337988,0.00168112,0.0004349963,0.00009612261,0.000009803497,0.0002012575,0.0001375411,0.0002041998],"category_scores_gemma":[0.02042325,0.0001378885,0.0003550503,0.0002274084,0.0002972727,0.0001075044,0.00004226726,0.0008193832,0.000001438028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004689693,"about_ca_system_score_gemma":0.0003578412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009992239,"about_ca_topic_score_gemma":0.0001784941,"domain_scores_codex":[0.996963,0.0001291849,0.001319647,0.0001918872,0.001017699,0.0003785655],"domain_scores_gemma":[0.9950765,0.002383016,0.0007867759,0.000293848,0.0009587364,0.0005011691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6002896,0.0003125661,0.001659589,0.00008608386,0.0005094652,0.00001762013,0.0006114611,0.000007388345,0.2823187,0.0000305827,0.01598932,0.09816759],"study_design_scores_gemma":[0.9603471,0.00879534,0.002310538,0.001010468,0.0005650077,0.0001324024,0.0001703922,0.0007120167,0.003344737,0.000120547,0.02238276,0.0001087092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975027,0.000768534,0.001699362,0.01650619,0.002570271,0.002571878,0.000008049233,0.0000195666,0.0008291011],"genre_scores_gemma":[0.9818141,0.000871893,0.00940719,0.0001404653,0.006987143,0.0000295795,0.000006247411,0.00003431615,0.0007090286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3600574,"threshold_uncertainty_score":0.9878281,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2043591841","doi":"10.1056/nejmoa1014656","title":"Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":976,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; University of Toronto","funders":"","keywords":"Teriflunomide; Multiple sclerosis; Expanded Disability Status Scale; Medicine; Placebo; Randomized controlled trial; Clinical endpoint; Internal medicine; Physical therapy; Psychiatry; Alternative medicine; Pathology; Fingolimod","retraction":null,"screen_n_in":null,"score":{"opus":0.1957887722186325,"gpt":0.3466526090408081,"spread":0.1508638368221756,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004810168,0.0001967873,0.00184122,0.0003665746,0.00006241905,0.00000503415,0.0001707929,0.00008363869,0.0001961169],"category_scores_gemma":[0.01441263,0.0001135476,0.0003872995,0.0001690136,0.0004462538,0.0001080182,0.00003882248,0.0003236934,0.00000118911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005360473,"about_ca_system_score_gemma":0.00021455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003137837,"about_ca_topic_score_gemma":0.00003124185,"domain_scores_codex":[0.9972408,0.0002580387,0.001349719,0.0001571857,0.0006917287,0.0003025047],"domain_scores_gemma":[0.9961452,0.001829512,0.0007707426,0.0002239767,0.0006614419,0.0003691338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8855755,0.0002041385,0.0009399927,0.00009592255,0.0004841588,0.00001582405,0.002400197,0.000001484234,0.02151943,0.0000365957,0.007088439,0.08163832],"study_design_scores_gemma":[0.9792888,0.005394962,0.002097668,0.001327786,0.0006453396,0.00007661917,0.0002618945,0.000167952,0.004582734,0.0003090326,0.00575744,0.00008972698],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723623,0.002687242,0.009330406,0.007141179,0.002132418,0.002918874,0.00001060514,0.00002626319,0.003390688],"genre_scores_gemma":[0.9768819,0.002171714,0.01730565,0.0001543555,0.002975457,0.00001862263,0.000004291313,0.00002963596,0.000458355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09371335,"threshold_uncertainty_score":0.9938894,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139344244","doi":"10.1212/01.wnl.0000156155.19270.f8","title":"Multiple Sclerosis Severity Score","year":2005,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Ministère de la Santé et des Services sociaux","keywords":"Expanded Disability Status Scale; Medicine; Multiple sclerosis; Disease; Physical therapy; Severity of illness; Cross-sectional study; Physical disability; Physical medicine and rehabilitation; Internal medicine; Pathology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.1000392581115146,"gpt":0.3088179758071572,"spread":0.2087787176956426,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001512877,0.0001420812,0.0002979177,0.0001060548,0.000116852,0.000009302255,0.0001222537,0.0001161095,0.0004127572],"category_scores_gemma":[0.0006457067,0.0001224698,0.00009388767,0.000156185,0.0002137459,0.00006644165,0.0001677434,0.0004143524,0.0004831708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002838909,"about_ca_system_score_gemma":0.0000410824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001066018,"about_ca_topic_score_gemma":0.0003165008,"domain_scores_codex":[0.9986205,0.00008694418,0.0001976048,0.0003630012,0.0002695885,0.0004624205],"domain_scores_gemma":[0.9990866,0.0002167731,0.00003777873,0.0003759622,0.0001013707,0.0001814764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001743426,0.0004994413,0.7687934,0.00006063966,0.0001047213,0.00005917008,0.0002537596,0.00004378717,0.07539518,0.00004989167,0.02191216,0.1310844],"study_design_scores_gemma":[0.001831675,0.0005666395,0.9117753,0.000009572143,0.00001633879,0.00004293258,0.000003420863,0.001906027,0.002939984,0.000007845325,0.08081357,0.00008673134],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760669,0.0001764077,0.0000324882,0.01923025,0.0001286878,0.0003413343,0.00001037218,0.0001439787,0.003869602],"genre_scores_gemma":[0.9914603,0.0004028159,0.0007282544,0.006632962,0.000457641,0.00004923933,0.000007925294,0.00002336859,0.0002375482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1429819,"threshold_uncertainty_score":0.6210344,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107008240","doi":"10.1002/ana.21867","title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial","year":2009,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":939,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Ottawa Hospital; University of Toronto","funders":"","keywords":"Rituximab; Medicine; Placebo; Clinical endpoint; Internal medicine; Randomization; Multiple sclerosis; Gastroenterology; Adverse effect; Expanded Disability Status Scale; Hazard ratio; Surgery; Randomized controlled trial; Confidence interval; Pathology; Immunology; Lymphoma","retraction":null,"screen_n_in":null,"score":{"opus":0.09218066435206093,"gpt":0.3421997759005153,"spread":0.2500191115484544,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001453704,0.0003068682,0.002939696,0.0005141011,0.00004370331,0.000009541654,0.0002072863,0.0001787357,0.00001330176],"category_scores_gemma":[0.004290682,0.0002039716,0.0003740464,0.0003068021,0.0005545301,0.0001239346,0.00009493891,0.0004246673,0.00000374395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001211534,"about_ca_system_score_gemma":0.0001126365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000056715,"about_ca_topic_score_gemma":0.00002432165,"domain_scores_codex":[0.9958771,0.0007646749,0.001493082,0.0005367012,0.0007420395,0.0005864297],"domain_scores_gemma":[0.9959399,0.00171377,0.0008468386,0.000479908,0.0008720103,0.0001475881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830818,0.00728805,0.005674904,0.00007721034,0.0004897082,0.00002410317,0.0003742978,0.00002479213,0.0006519209,0.000004837636,0.0003671833,0.001941164],"study_design_scores_gemma":[0.8380338,0.008647084,0.151554,0.0002052379,0.0001164952,8.924189e-7,0.000009927257,0.0002920798,0.0009870566,0.000009000735,0.00002892415,0.0001155288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831866,0.0003881528,0.000003468528,0.00519412,0.00008345716,0.01046922,0.00003947288,0.00002643591,0.0006090974],"genre_scores_gemma":[0.9975712,0.0003178184,0.0002448731,0.001210936,0.00007897128,0.0004772569,0.00005046635,0.00002215696,0.00002633319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.145879,"threshold_uncertainty_score":0.8317721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2790816436","doi":"10.1016/s0140-6736(18)30475-6","title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":925,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NeuroRx Research (Canada); McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Placebo; Expanded Disability Status Scale; Clinical endpoint; Multiple sclerosis; Internal medicine; Clinical trial; Randomized controlled trial; Physical therapy; Immunology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2042846764689597,"gpt":0.4062930836065874,"spread":0.2020084071376277,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001498198,0.0002925253,0.000944902,0.0001718238,0.0003201332,0.00008259904,0.0004572153,0.00008135362,0.0004523698],"category_scores_gemma":[0.0009814678,0.0001829242,0.0001210144,0.0004864106,0.0004970546,0.0001316796,0.000306746,0.0006237704,0.0001766612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001467495,"about_ca_system_score_gemma":0.0001705356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002388104,"about_ca_topic_score_gemma":0.0007507295,"domain_scores_codex":[0.9973205,0.0003275032,0.0004367225,0.0004946401,0.0006460098,0.0007745724],"domain_scores_gemma":[0.9976111,0.0008844561,0.0001364193,0.0009613038,0.0002358812,0.0001708318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9331198,0.002321623,0.01634851,0.00008655238,0.0006895267,0.00007236238,0.008312092,0.0000035408,0.00533758,0.000008667622,0.009301723,0.02439801],"study_design_scores_gemma":[0.9318717,0.002929788,0.05423444,0.0002273034,0.0001227938,0.000005805641,0.002968436,0.0006432643,0.004623657,0.000007263237,0.002129775,0.0002358477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843973,0.000652665,0.000009120924,0.002590065,0.0002975173,0.006604021,0.00004364678,0.0001190695,0.005286619],"genre_scores_gemma":[0.9953964,0.000179981,0.0002140676,0.0002571267,0.0019978,0.001684684,0.00002174949,0.00004018702,0.00020804],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03788592,"threshold_uncertainty_score":0.7459434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2280334572","doi":"10.1016/s1474-4422(15)00393-2","title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","year":2016,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":863,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Chugai Pharmaceutical; European Commission; Sanofi; Bayer HealthCare; McGill University; Eli Lilly and Company; CSL Behring; Medical Research Council; Biogen; Pfizer; Teva Pharmaceutical Industries; National Institutes of Health; Siemens; National Research Foundation","keywords":"Multiple sclerosis; Medicine; Magnetic resonance imaging; Spinal cord; Medical physics; Disease; Clinically isolated syndrome; Expert opinion; Radiology; Pathology; Intensive care medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.4538873705448648,"gpt":0.4632092373291845,"spread":0.009321866784319732,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001550198,0.0004915996,0.003140766,0.000128049,0.0002255539,0.00001974875,0.0009535993,0.0002960577,0.0001502389],"category_scores_gemma":[0.008962647,0.0001970904,0.000756034,0.0002212726,0.001047767,0.00001594059,0.0005022715,0.0005778946,0.00006808639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002515376,"about_ca_system_score_gemma":0.0001814639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006253845,"about_ca_topic_score_gemma":0.00005012429,"domain_scores_codex":[0.996462,0.0007322054,0.001085033,0.000577264,0.0003549076,0.000788619],"domain_scores_gemma":[0.9822025,0.01498561,0.0005612586,0.0016027,0.0005557406,0.0000922133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005272091,0.00006140416,0.0003180678,0.006813702,0.0007001184,0.000008029598,0.00003655095,7.53868e-7,0.0000402961,0.00005169714,0.2971317,0.6943105],"study_design_scores_gemma":[0.001811829,0.0004556529,0.001034977,0.004436057,0.0009260976,0.0000586346,0.000008428365,0.00008373873,0.0000183332,0.00003818571,0.9909576,0.0001705218],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008140963,0.9392671,0.00004236793,0.0549385,0.0007514897,0.003724671,0.00100216,0.0000673695,0.0001249523],"genre_scores_gemma":[0.00020184,0.9905226,0.0003069486,0.002532259,0.002743339,0.003359547,0.0000258895,0.00009531224,0.0002123157],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.69414,"threshold_uncertainty_score":0.9993853,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1833759296","doi":"10.1038/80516","title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand","year":2000,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":826,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Myelin basic protein; Multiple sclerosis; Peptide; Myelin; Immunotherapy; Immunology; Ligand (biochemistry); Medicine; Peptide vaccine; Magnetic resonance imaging; Antigen; Biology; Internal medicine; Immune system; Epitope; Biochemistry; Central nervous system; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.08052038373286932,"gpt":0.369205776705015,"spread":0.2886853929721457,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003227263,0.0004544209,0.001560346,0.0003161606,0.0001787574,0.000008773819,0.000614454,0.00053177,0.000172594],"category_scores_gemma":[0.006192029,0.0002530892,0.0003059647,0.001068246,0.001622451,0.0001544407,0.000169416,0.002074164,0.000003659841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009555693,"about_ca_system_score_gemma":0.0004309481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004831472,"about_ca_topic_score_gemma":0.0007843473,"domain_scores_codex":[0.9936482,0.0007157709,0.002074359,0.0008843935,0.002006183,0.000671093],"domain_scores_gemma":[0.9966728,0.0004928863,0.0005764817,0.001334871,0.0005463802,0.0003765588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4468262,0.007287169,0.006138178,0.0004060863,0.0005767256,0.0000817797,0.003418692,0.0000348553,0.4541523,0.00000897783,0.00542572,0.07564337],"study_design_scores_gemma":[0.6511812,0.04703472,0.2090313,0.007317426,0.0005530958,0.00003860312,0.001320536,0.001402906,0.07687138,0.00003287824,0.004737508,0.0004784942],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883581,0.001153325,0.000008156163,0.005231854,0.0003287905,0.004222676,0.0001290246,0.00004322753,0.0005248414],"genre_scores_gemma":[0.9947755,0.0006761577,0.0007234851,0.0003951304,0.001991055,0.0001677964,0.00008599424,0.00005042655,0.001134393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3772809,"threshold_uncertainty_score":0.9999921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2161944076","doi":"10.1212/01.wnl.0000259422.44235.a8","title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","year":2007,"lang":"en","type":"review","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":753,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Acute disseminated encephalomyelitis; Medicine; Multiple sclerosis; Neuromyelitis optica; Demyelinating Disorder; Clinically isolated syndrome; Pediatrics; Neuropsychology; Pediatric Neurology; Neurology; Psychiatry; Cognition","retraction":null,"screen_n_in":null,"score":{"opus":0.2170855496585863,"gpt":0.3687150357244228,"spread":0.1516294860658365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003907775,0.0004440299,0.001737769,0.0006258145,0.0002529007,0.00001404189,0.00012925,0.0006500201,0.00003823712],"category_scores_gemma":[0.002858175,0.0003584701,0.0004402545,0.0004805712,0.0004555482,0.00001566198,0.0001617011,0.0009263536,0.00005258032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003558355,"about_ca_system_score_gemma":0.0002518651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003420635,"about_ca_topic_score_gemma":0.00009596154,"domain_scores_codex":[0.9973133,0.0002475947,0.0007425554,0.0007580954,0.0002368101,0.0007016062],"domain_scores_gemma":[0.9948375,0.004103478,0.0002655882,0.0004025174,0.0001517774,0.0002391047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004272276,0.0003087438,0.001289371,0.01923528,0.0004404465,0.00004659075,0.00005006381,3.804564e-7,0.000007523516,0.0001242532,0.003347934,0.9747222],"study_design_scores_gemma":[0.003371731,0.001750341,0.003442918,0.0005850162,0.001811067,0.0001857748,0.000004437848,0.00004638621,4.399288e-7,0.00009116816,0.9883801,0.0003305597],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009361863,0.9921257,0.00001376132,0.0008995664,0.0003362686,0.004447837,0.0002549829,0.0001408431,0.0008448714],"genre_scores_gemma":[0.0007504996,0.9974828,0.0005048903,0.0001926561,0.0002076082,0.000458782,0.0002082686,0.0001076201,0.00008685247],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9850322,"threshold_uncertainty_score":0.9998868,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105167551","doi":"10.1016/s0140-6736(11)61649-8","title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; McGill University; University of British Columbia","funders":"F. Hoffmann-La Roche; IC Design Education Center; Biogen Idec; Biogen","keywords":"Ocrelizumab; Medicine; Placebo; Interferon beta-1a; Multiple sclerosis; Clinical endpoint; Internal medicine; Population; Clinical trial; Immunology; Rituximab; Interferon beta; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1512711031892404,"gpt":0.3369648857764854,"spread":0.185693782587245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002503586,0.0003134323,0.001530495,0.0001654215,0.0002474616,0.00004548796,0.0004209792,0.000121803,0.0003247382],"category_scores_gemma":[0.008644371,0.0001913394,0.0003053914,0.000315663,0.0002243182,0.0001176106,0.0001802931,0.0007287571,0.0001198809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001522038,"about_ca_system_score_gemma":0.0001064528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003625441,"about_ca_topic_score_gemma":0.000210199,"domain_scores_codex":[0.9967446,0.00054957,0.0007700281,0.0004476493,0.0005772878,0.0009108167],"domain_scores_gemma":[0.9969218,0.001651211,0.0002403866,0.0008718886,0.0001302564,0.0001844312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9716385,0.0009861458,0.003698689,0.0000739419,0.0003062981,0.00003424817,0.005106569,0.000009577574,0.003867136,0.0000150084,0.005216552,0.009047333],"study_design_scores_gemma":[0.9813511,0.0004801016,0.006460778,0.0006434472,0.0001443552,0.000007555006,0.001188571,0.007328187,0.001298055,0.00002626105,0.0008647009,0.0002068517],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753087,0.001383549,0.0001028821,0.001942685,0.0004191779,0.007554144,0.00002428939,0.0001853033,0.01307925],"genre_scores_gemma":[0.9942084,0.001104091,0.001481059,0.0004092022,0.001371219,0.0009513403,0.00001000339,0.00004666331,0.000418034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01889966,"threshold_uncertainty_score":0.9997062,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143953700","doi":"10.1093/brain/awq118","title":"The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability","year":2010,"lang":"en","type":"article","venue":"Brain","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":718,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"London Health Sciences Centre; Western University","funders":"Porticus Foundation; Fondazione Italiana Sclerosi Multipla","keywords":"Multiple sclerosis; Natural history; Expanded Disability Status Scale; Medicine; Cohort; Confidence interval; Natural history study; Pediatrics; Disease; Physical therapy; Internal medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.04227848539635986,"gpt":0.2990271467042017,"spread":0.2567486613078418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146334,0.0001689779,0.0003243606,0.00006207983,0.0001745366,0.00001871742,0.0001945488,0.00007178921,0.0001026681],"category_scores_gemma":[0.006979814,0.0001051841,0.0001247188,0.0001476395,0.001442287,0.00005663632,0.0001806859,0.0005139639,0.000003689738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009144925,"about_ca_system_score_gemma":0.0001239517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001933337,"about_ca_topic_score_gemma":0.004775948,"domain_scores_codex":[0.9982591,0.0002019693,0.0003298171,0.0003590451,0.0005355728,0.0003145378],"domain_scores_gemma":[0.9965951,0.002281212,0.00009141278,0.000677242,0.0001971279,0.0001579242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004917129,0.0007937672,0.9210474,0.0000836572,0.00008815806,0.000003480467,0.0003410904,1.075962e-7,0.06064332,0.000009082682,0.002535655,0.01396257],"study_design_scores_gemma":[0.002946726,0.0003801187,0.9938923,0.00005581535,0.00003353307,0.00000140653,0.0001440015,0.0002212598,0.0002044068,0.000004006438,0.002015817,0.000100583],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943223,0.001072369,0.000003537601,0.003042698,0.0002512608,0.001126639,0.0000113328,0.00004961025,0.0001202277],"genre_scores_gemma":[0.9986644,0.00005231175,0.0001902618,0.0001415116,0.00007953517,0.0001079181,0.000007667551,0.00001808066,0.0007382732],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07284493,"threshold_uncertainty_score":0.8355994,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2562977489","doi":"10.1007/s00401-016-1653-y","title":"An updated histological classification system for multiple sclerosis lesions","year":2016,"lang":"en","type":"article","venue":"Acta Neuropathologica","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":699,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; Queen's University; Montreal Neurological Institute and Hospital","funders":"Austrian Science Fund; Deutsche Forschungsgemeinschaft","keywords":"Microglia; Multiple sclerosis; Myelin; Pathology; Luxol fast blue stain; Lesion; Proteolipid protein 1; Medicine; Immunohistochemistry; Myelin basic protein; Pathogenesis; Demyelinating disease; Central nervous system; Immunology; Inflammation; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1913119945499814,"gpt":0.3350263381843445,"spread":0.1437143436343631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004827273,0.0002481021,0.0004550037,0.0001387045,0.0003790912,0.00002968362,0.0003083515,0.0001740389,0.00008618525],"category_scores_gemma":[0.002417041,0.0001351394,0.000161817,0.0002096749,0.0003174563,0.0001559531,0.0001156788,0.0001709562,0.00009424448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001816388,"about_ca_system_score_gemma":0.00004730199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004385662,"about_ca_topic_score_gemma":0.000003046669,"domain_scores_codex":[0.9975809,0.0003526126,0.0004105253,0.0007719293,0.0003373768,0.0005466465],"domain_scores_gemma":[0.997818,0.0005992186,0.0001579023,0.0007914415,0.0003337507,0.0002996692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0004852961,0.0003364075,0.01828352,0.00003141592,0.0000158601,0.00003144305,0.00003425093,2.730403e-7,0.9573435,0.0002521499,0.004179357,0.01900654],"study_design_scores_gemma":[0.002827682,0.001628997,0.9598954,0.0001103089,0.00007289591,0.00008326179,0.0002314074,0.000769856,0.02159397,0.00001188515,0.01253665,0.0002376686],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883499,0.00004428402,0.002525887,0.005496306,0.0002126746,0.001414106,0.0001566644,0.0007081913,0.001092003],"genre_scores_gemma":[0.9958428,0.000199666,0.002732795,0.0002939724,0.0001644647,0.0004244,0.00008064835,0.00003845023,0.0002227646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9416119,"threshold_uncertainty_score":0.5510824,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2114753322","doi":"10.1076/clin.16.3.381.13859","title":"Minimal Neuropsychological Assessment of MS Patients: A Consensus Approach","year":2002,"lang":"en","type":"review","venue":"The Clinical Neuropsychologist","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":653,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Health Sciences Centre; Foothills Medical Centre","funders":"Marshall Space Flight Center; Biogen","keywords":"Neuropsychology; Neuropsychological assessment; Psychology; Cognition; Executive dysfunction; Clinical psychology; Working memory; Depression (economics); Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.4236155759339028,"gpt":0.5347718299731651,"spread":0.1111562540392623,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002399013,0.0008959371,0.004895821,0.0002068343,0.0001886414,0.00004283288,0.001390005,0.0007229184,0.0002912942],"category_scores_gemma":[0.007912621,0.0004604039,0.002341903,0.0008712895,0.004426737,0.00002137395,0.0007654909,0.00397579,0.0001963216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000669842,"about_ca_system_score_gemma":0.0001561778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006629919,"about_ca_topic_score_gemma":4.201274e-7,"domain_scores_codex":[0.9883001,0.004334248,0.003609719,0.001718051,0.001173294,0.0008646089],"domain_scores_gemma":[0.989106,0.005823463,0.001534251,0.002682157,0.0004241321,0.000429973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002703922,0.007218128,0.003573831,0.004018179,0.0006355113,0.0001299796,0.00001399636,4.022436e-7,7.667633e-7,0.00004347935,0.04008694,0.9440084],"study_design_scores_gemma":[0.002401761,0.003381895,0.1878228,0.001638872,0.001105644,0.0001343377,0.00001010637,0.00004594945,1.723053e-8,0.000004714484,0.8030833,0.0003706533],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001965308,0.9283082,0.00002871847,0.0009869356,0.001461233,0.005539438,0.0002532152,0.0002076251,0.06124935],"genre_scores_gemma":[0.00153892,0.994253,0.001509515,0.0008987241,0.0006465823,0.0002557136,0.0001025084,0.0001299406,0.0006650499],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9436377,"threshold_uncertainty_score":0.9997848,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135440918","doi":"10.1177/1352458508096878","title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","year":2008,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"Multiple Sclerosis Society","keywords":"Multiple sclerosis; Differential diagnosis; Medical diagnosis; Medicine; Demyelinating Disorder; McDonald criteria; Neurology; Intensive care medicine; Pathology; Pediatrics; Immunology; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.1716670000508236,"gpt":0.2906815693544226,"spread":0.119014569303599,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006759436,0.0007902399,0.001819183,0.0008791691,0.001255091,0.0001073908,0.00064085,0.0003702938,0.0007602058],"category_scores_gemma":[0.004764867,0.000658446,0.001061713,0.001089046,0.001402123,0.0002366159,0.0004326563,0.001576985,0.00006788594],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004201653,"about_ca_system_score_gemma":0.0004162467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004262808,"about_ca_topic_score_gemma":0.00006770514,"domain_scores_codex":[0.9929104,0.000518586,0.00183262,0.0009206472,0.002286004,0.001531676],"domain_scores_gemma":[0.9942213,0.001332595,0.0008064487,0.0009802849,0.001522259,0.00113714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001687155,0.002976731,0.7636421,0.0002125819,0.001020437,0.00008273592,0.001593929,0.0001205176,0.2096657,0.000009076106,0.01152326,0.007465807],"study_design_scores_gemma":[0.01674309,0.0006830209,0.9159927,0.0008841623,0.0002561842,0.0006868229,0.0008596646,0.00524272,0.05755727,0.000008086802,0.0004969883,0.0005892462],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937423,0.001691833,0.0007458919,0.0007136002,0.0005229734,0.001372318,0.0001893674,0.0002163052,0.0008054281],"genre_scores_gemma":[0.9781156,0.008786117,0.01141498,0.000128178,0.0008898636,0.0002773955,0.00005417736,0.0001480709,0.0001856242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1523506,"threshold_uncertainty_score":0.9995867,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3171747481","doi":"10.1016/s1474-4422(21)00095-8","title":"2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","year":2021,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; University of Toronto; University of British Columbia","funders":"National Institute of Neurological Disorders and Stroke; Sanofi Genzyme; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; Siemens; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Multiple Sclerosis Society; Schweizerische Multiple Sklerose Gesellschaft; Multiple Sclerosis Society of Canada; European Commission; GlaxoSmithKline España; EMD Serono; UCB; Novartis; Fondazione Italiana Sclerosi Multipla; Roche España; F. Hoffmann-La Roche; Pfizer; Biogen; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Chugai Pharmaceutical; MedDay Pharmaceuticals; Ministero della Salute; UCLH Biomedical Research Centre; Bayer HealthCare; Sanofi; MedImmune; National Multiple Sclerosis Society","keywords":"Multiple sclerosis; Consensus conference; Medicine; Internal medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.3280089237450736,"gpt":0.3659037303031907,"spread":0.03789480655811717,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005151982,0.0003844275,0.002261898,0.0001875074,0.0001363427,0.00002445187,0.0004000619,0.0001923927,0.0002609781],"category_scores_gemma":[0.002440097,0.0001829232,0.0002368505,0.0006530903,0.0005197237,0.00002217079,0.0003496492,0.001454527,0.00004583161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005080037,"about_ca_system_score_gemma":0.0001811836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001115132,"about_ca_topic_score_gemma":0.0002699812,"domain_scores_codex":[0.9959798,0.0018864,0.0006430513,0.0005280641,0.0004108483,0.0005518761],"domain_scores_gemma":[0.9908456,0.007071941,0.0003919723,0.00137374,0.0002462999,0.00007041353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001527152,0.00125973,0.03932974,0.003451492,0.00131084,0.00005637118,0.000297129,0.00004833245,0.000005218671,0.0001955622,0.1501097,0.8024088],"study_design_scores_gemma":[0.002080096,0.0006894577,0.04818245,0.004189118,0.0002908076,0.000007448658,0.00001283253,0.00003968737,0.000001830475,0.000002288311,0.9443449,0.0001591123],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02073729,0.8776407,0.000006860547,0.09032843,0.0007223281,0.008263672,0.001609249,0.00006866672,0.0006227668],"genre_scores_gemma":[0.001250783,0.9957113,0.0001831354,0.001943385,0.0001911238,0.0003505129,0.0002147797,0.00006005833,0.000094966],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8022496,"threshold_uncertainty_score":0.7459391,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2028842616","doi":"10.1016/j.apmr.2013.04.020","title":"Effects of Exercise Training on Fitness, Mobility, Fatigue, and Health-Related Quality of Life Among Adults With Multiple Sclerosis: A Systematic Review to Inform Guideline Development","year":2013,"lang":"en","type":"review","venue":"Archives of Physical Medicine and Rehabilitation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":625,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"CINAHL; PsycINFO; Data extraction; MEDLINE; Physical therapy; Medicine; Aerobic exercise; Quality of life (healthcare); Cochrane Library; Physical fitness; Rehabilitation; International Classification of Functioning, Disability and Health; Aerobic capacity; Physical medicine and rehabilitation; Checklist; Randomized controlled trial; Gerontology; Psychology; Psychological intervention; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.1199691662926452,"gpt":0.3919984992899905,"spread":0.2720293329973453,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001480346,0.0004413293,0.006419452,0.0004135919,0.00006936875,0.000002924403,0.000134959,0.0000927279,0.000002355687],"category_scores_gemma":[0.01643223,0.000240263,0.0002695439,0.0005068486,0.001025318,0.00007142051,0.000128153,0.000343694,6.600757e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004268126,"about_ca_system_score_gemma":0.0002842067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004232821,"about_ca_topic_score_gemma":0.00002421382,"domain_scores_codex":[0.9947715,0.0005171968,0.003111154,0.000484152,0.0008479899,0.000267995],"domain_scores_gemma":[0.9854449,0.01175069,0.001622756,0.0004432821,0.0003533179,0.0003850739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001103406,0.0002903342,0.00009713198,0.6921424,0.0002615736,1.325159e-7,0.01391608,9.043167e-7,0.00001995384,0.0000261008,0.00004511351,0.2930899],"study_design_scores_gemma":[0.002162416,0.004317153,0.02814052,0.9625863,0.0007432328,5.091849e-7,0.001650283,0.0001050268,0.000007830117,0.00002055421,0.00008418168,0.0001819906],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02800893,0.9554371,0.00005014422,0.0009073933,0.00001740975,0.0155128,0.00001725023,0.00001955525,0.00002938733],"genre_scores_gemma":[0.05378774,0.9403962,0.003830009,0.00005837864,0.00002521497,0.001778055,0.00008182408,0.00003324949,0.000009296303],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.292908,"threshold_uncertainty_score":0.9918528,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2100830657","doi":"10.1016/s1474-4422(09)70043-2","title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","year":2009,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":616,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"","keywords":"Multiple sclerosis; AMPA receptor; Neuroscience; Neuroprotection; Glutamate receptor; Ionotropic effect; Medicine; Biology; Receptor; Internal medicine; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.1872785178967508,"gpt":0.360361649064981,"spread":0.1730831311682301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006938091,0.0004387263,0.003432062,0.0003363016,0.00009890911,0.00001317617,0.0004588983,0.0003922447,0.00003514754],"category_scores_gemma":[0.001199277,0.0002764414,0.0002695738,0.0005779159,0.000711577,0.00003343082,0.000404325,0.001418958,0.00002654809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007470198,"about_ca_system_score_gemma":0.0002275737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001179264,"about_ca_topic_score_gemma":0.0003166198,"domain_scores_codex":[0.9968527,0.0007612346,0.000763436,0.0005819664,0.0002907364,0.0007499506],"domain_scores_gemma":[0.9969419,0.001755245,0.0003133056,0.0008026636,0.00007512367,0.000111825],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002435572,0.000114444,0.0006025789,0.003151864,0.0001813409,0.00002518298,0.00007929757,0.000004881059,0.0002547221,0.00003245747,0.001525774,0.9937839],"study_design_scores_gemma":[0.004277786,0.002235392,0.06431874,0.006200598,0.0006644881,0.000121599,0.000008699947,0.0002915487,0.00002257759,0.00003500831,0.9214647,0.0003588051],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008131299,0.9875264,0.000003312715,0.002370836,0.0001034642,0.001522929,0.00008987,0.00005477545,0.0001971488],"genre_scores_gemma":[0.0136819,0.9850692,0.00005399864,0.0004832694,0.00038623,0.0001772178,0.00003449932,0.00005128485,0.00006241901],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9934251,"threshold_uncertainty_score":0.9999688,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4309374247","doi":"10.1016/s1474-4422(22)00289-7","title":"Multiple sclerosis progression: time for a new mechanism-driven framework","year":2022,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":615,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; University of Manitoba; Hotchkiss Brain Institute; McGill University; Montreal Neurological Institute and Hospital","funders":"University College London Hospitals NHS Foundation Trust; Deutsche Forschungsgemeinschaft; National Institutes of Health; European Committee for Treatment and Research in Multiple Sclerosis; Multiple Sclerosis Society; National Institute of Neurological Disorders and Stroke; UCLH Biomedical Research Centre; Università degli Studi di Napoli Federico II; National Institute for Health and Care Research; National Multiple Sclerosis Society","keywords":"Mechanism (biology); Multiple sclerosis; Computer science; Medicine; Neuroscience; Psychology; Epistemology; Immunology; Philosophy","retraction":null,"screen_n_in":null,"score":{"opus":0.2652376272862743,"gpt":0.4103880129017697,"spread":0.1451503856154954,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007276228,0.0005651333,0.003370953,0.0001825134,0.0004660296,0.00003608282,0.001055001,0.0004504179,0.001363393],"category_scores_gemma":[0.003103925,0.0003382192,0.0007936941,0.000470974,0.0002170395,0.00002937223,0.001078472,0.002157327,0.0002745347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008080413,"about_ca_system_score_gemma":0.0004228088,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001354643,"about_ca_topic_score_gemma":0.000005567415,"domain_scores_codex":[0.9961306,0.0007865002,0.0005985606,0.0008641726,0.0005715925,0.001048578],"domain_scores_gemma":[0.9927778,0.00507479,0.0004033986,0.001444194,0.00006300495,0.0002368524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006229245,0.0001126726,0.00001755761,0.004552136,0.0005373959,0.0000349455,0.0001181333,0.000001365609,0.00001611787,0.000377402,0.06437071,0.9292386],"study_design_scores_gemma":[0.001321862,0.00122009,0.0000488416,0.00218799,0.0007246352,0.00009838226,0.000003867579,0.0002233176,0.000002290276,0.0004809735,0.993435,0.0002527599],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001485356,0.9818509,0.0002425084,0.01021633,0.000621626,0.006187862,0.0002569843,0.0002705799,0.0003383074],"genre_scores_gemma":[0.00001129743,0.9864589,0.003225461,0.002454837,0.003275628,0.003415535,0.0001883002,0.0001641214,0.0008059197],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9290643,"threshold_uncertainty_score":0.999907,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115404493","doi":"10.1002/ana.20851","title":"Quantifying axonal loss after optic neuritis with optical coherence tomography","year":2006,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Eye Institute","keywords":"Optical coherence tomography; Nerve fiber layer; Optic neuritis; Ophthalmology; Medicine; Retinal; Optic nerve; Multiple sclerosis; Glaucoma","retraction":null,"screen_n_in":null,"score":{"opus":0.0969166560663867,"gpt":0.3530318459417835,"spread":0.2561151898753968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001550997,0.0001668776,0.0004183125,0.0001947855,0.00004917952,0.00001141652,0.0001194798,0.00008886,0.0001104112],"category_scores_gemma":[0.0001358523,0.0001305392,0.0001191673,0.0002806229,0.0007464327,0.0000651837,0.00009658124,0.0003203853,0.00001795217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000001991512,"about_ca_system_score_gemma":0.00004603052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001220856,"about_ca_topic_score_gemma":0.0001233407,"domain_scores_codex":[0.9983312,0.00008421405,0.0002945275,0.0003673966,0.0004073568,0.0005152809],"domain_scores_gemma":[0.9989286,0.0002950266,0.00006762127,0.0002894207,0.0002946059,0.0001247074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003894684,0.000607548,0.9745668,0.0002302343,0.0001476198,0.002397166,0.00004314576,0.00004957526,0.01198356,0.0007974995,0.002661432,0.002620748],"study_design_scores_gemma":[0.0008938127,0.002396231,0.9905204,0.00005382178,0.00002587582,0.0002920451,0.000005398361,0.0001211064,0.003782656,0.00006890815,0.001731416,0.0001083741],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869031,0.0005670366,0.00004047392,0.01058261,0.00004792352,0.0002747979,0.00001525393,0.0000381387,0.001530645],"genre_scores_gemma":[0.997208,0.0001736937,0.0006593065,0.00170072,0.0001251539,0.00006490498,0.000006881603,0.00002090997,0.00004042587],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01595356,"threshold_uncertainty_score":0.5323234,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366064463","doi":"10.1002/ana.64","title":"European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis","year":2001,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":608,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Glatiramer acetate; Medicine; Placebo; Multiple sclerosis; Magnetic resonance imaging; Randomized controlled trial; Confidence interval; Clinical trial; Lesion; Nuclear medicine; Internal medicine; Surgery; Radiology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04746573707919739,"gpt":0.287752972457593,"spread":0.2402872353783956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008127887,0.0002438813,0.001104157,0.0003372726,0.00008064075,0.000008371715,0.0001839177,0.00003721152,0.000005000861],"category_scores_gemma":[0.00362524,0.0001561333,0.000134347,0.0002941107,0.0005534054,0.00007385556,0.0001306926,0.0003286211,9.084026e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001269626,"about_ca_system_score_gemma":0.00005823503,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006534826,"about_ca_topic_score_gemma":0.004799175,"domain_scores_codex":[0.9964137,0.001733841,0.0005092507,0.0004172277,0.0005061861,0.0004197985],"domain_scores_gemma":[0.9969379,0.001665066,0.0003412546,0.0005070984,0.0003358911,0.0002128113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5261269,0.0008861229,0.4651174,0.000079014,0.0000871271,0.00002952275,0.0004858103,0.00005128838,0.0009544213,4.224773e-7,0.00001505235,0.006167004],"study_design_scores_gemma":[0.3924457,0.001472369,0.6046389,0.0002510309,0.00009397406,3.694039e-7,0.00001753947,0.0008970081,0.0001051039,0.000001206443,0.0000146762,0.00006216802],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914449,0.001152531,7.219824e-7,0.001640716,0.00008572821,0.005548222,0.00001072893,0.000008316501,0.0001081303],"genre_scores_gemma":[0.9987624,0.0007181702,0.000009388613,0.0003183334,0.00001758958,0.0001143371,0.000001615584,0.00003179882,0.00002642071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1395215,"threshold_uncertainty_score":0.9878745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164371036","doi":"10.1001/archneur.62.6.865","title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.","year":2005,"lang":"en","type":"article","venue":"PubMed","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":605,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Multiple sclerosis; Cerebrospinal fluid; Medical diagnosis; Medicine; Magnetic resonance imaging; Complement (music); Gold standard (test); Radiology; Pathology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.1171689337576219,"gpt":0.3212736640672331,"spread":0.2041047303096112,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001954797,0.0001731967,0.0007644417,0.0004887366,0.00005970399,0.00001439186,0.0002244721,0.00005664842,0.0001098143],"category_scores_gemma":[0.001833073,0.0001197389,0.000267016,0.001331776,0.0002199464,0.00005191006,0.0001049207,0.0001963953,0.000002162275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001934138,"about_ca_system_score_gemma":0.00005531563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004518946,"about_ca_topic_score_gemma":0.001794539,"domain_scores_codex":[0.9971998,0.0002795209,0.0008442822,0.0002913687,0.00085519,0.0005298124],"domain_scores_gemma":[0.9980196,0.0008112014,0.0002450719,0.0005097358,0.000288076,0.0001262919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001430593,0.0007681925,0.8713169,0.0001595546,0.001483254,0.000003654815,0.001178208,0.0001369817,0.0006411183,0.00002176487,0.006861285,0.1159985],"study_design_scores_gemma":[0.004042345,0.0001955297,0.9784138,0.00006554859,0.0004262538,7.961638e-7,0.00114652,0.0004031705,0.0121328,0.000007587371,0.003064661,0.0001009881],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867718,0.0007320895,0.00002672875,0.009533072,0.00002920767,0.00184313,0.0002583957,0.00001950232,0.0007860246],"genre_scores_gemma":[0.9946696,0.00141574,0.001057793,0.0001975966,0.00004797108,0.00253217,0.00002085107,0.00001373465,0.0000445174],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1158975,"threshold_uncertainty_score":0.4882809,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2896455370","doi":"10.1097/wco.0000000000000622","title":"Multiple sclerosis: clinical aspects","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":605,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Multiple sclerosis; Medicine; Disease; Intensive care medicine; Pathology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.5148347537597749,"gpt":0.5111649584201889,"spread":0.003669795339586002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001129153,0.0006449381,0.003433785,0.0007139568,0.00009459924,0.00002477028,0.0005179769,0.0007310294,0.0001374552],"category_scores_gemma":[0.004494496,0.0005092636,0.0009432192,0.0006661672,0.000746658,0.00005491225,0.0007442099,0.002773031,0.001037971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009740223,"about_ca_system_score_gemma":0.000561593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000924405,"about_ca_topic_score_gemma":0.00001064775,"domain_scores_codex":[0.9938602,0.001399989,0.001893101,0.001420091,0.0005144889,0.000912169],"domain_scores_gemma":[0.99593,0.001963674,0.0005001285,0.001053559,0.0001830848,0.00036952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001263852,0.0006774146,0.003944086,0.02116608,0.000126281,0.000009273178,0.00001947833,7.891637e-8,1.230646e-7,0.00003599249,0.04639569,0.9274991],"study_design_scores_gemma":[0.001898267,0.0009675007,0.01171166,0.02023953,0.0001271177,0.00005025597,0.000001630646,0.0000480169,8.133959e-8,0.00001483745,0.9646381,0.0003030014],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004493968,0.9792566,0.000007858641,0.0003289482,0.01753896,0.002298748,0.00006060519,0.0001150507,0.0003482989],"genre_scores_gemma":[0.00006047001,0.993601,0.00004415392,0.0000917189,0.00527172,0.0005734393,0.000236557,0.00009949739,0.00002149543],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9271961,"threshold_uncertainty_score":0.9997398,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4213066095","doi":"10.1016/s1474-4422(22)00009-6","title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","year":2022,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":601,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Disease; Multiple sclerosis; Retrospective cohort study; Amyotrophic lateral sclerosis; Epidemiology; MEDLINE","retraction":null,"screen_n_in":null,"score":{"opus":0.09145489506051398,"gpt":0.3021662337452696,"spread":0.2107113386847556,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007486242,0.0001121338,0.0003559414,0.0001089623,0.0001913091,0.000009897561,0.0001239147,0.00001699013,0.000004393193],"category_scores_gemma":[0.0003221969,0.0000804647,0.00002481148,0.0002615077,0.00007378652,0.00004824012,0.0002375538,0.0003084647,1.772032e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003690017,"about_ca_system_score_gemma":0.00005035333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008338899,"about_ca_topic_score_gemma":0.0001498793,"domain_scores_codex":[0.9984443,0.0004295804,0.0001645018,0.0003438714,0.000352458,0.0002652655],"domain_scores_gemma":[0.9990288,0.0004343717,0.0001207192,0.0002916731,0.0000736678,0.00005078557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009479181,0.0008300028,0.9762744,0.00007785239,0.00006904668,0.000003676367,0.003845662,0.006077529,0.002728367,0.00003679171,0.00003230609,0.000545215],"study_design_scores_gemma":[0.004427664,0.003616865,0.9484648,0.00001191981,0.00007550365,0.000002104652,0.0003542244,0.04236951,0.0005483407,0.0000511715,0.00001785935,0.00006000571],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846102,0.0000439295,0.0003259597,0.0110527,0.00003362744,0.003798576,0.0001019166,0.00002484932,0.000008270954],"genre_scores_gemma":[0.9976242,0.00006047626,0.00008224602,0.000219548,0.00006091881,0.001915755,0.00001398873,0.00001752966,0.0000053681],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03629199,"threshold_uncertainty_score":0.3281255,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4240233136","doi":"10.1056/nejmoa067597","title":"Natural History of Multiple Sclerosis with Childhood Onset","year":2007,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":591,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Multiple sclerosis; Expanded Disability Status Scale; Natural history; Neurology; Cohort; Medicine; Pediatrics; Rest (music); Physical therapy; Age of onset; Physical medicine and rehabilitation; Disease; Internal medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.04725591130764679,"gpt":0.2825215179903787,"spread":0.2352656066827319,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001815324,0.0001905421,0.0007836541,0.0004476758,0.00003477459,0.000002181415,0.0001619108,0.0000584751,0.0001681754],"category_scores_gemma":[0.002369619,0.0001059341,0.0001074356,0.0002289237,0.0004179797,0.00009174514,0.00003376831,0.0006687191,0.000002032774],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003150522,"about_ca_system_score_gemma":0.000496521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002045014,"about_ca_topic_score_gemma":0.0002260642,"domain_scores_codex":[0.9975061,0.00006535772,0.0007282122,0.000147344,0.001213692,0.0003392316],"domain_scores_gemma":[0.9974394,0.0007603103,0.0004712739,0.0002296585,0.0006238045,0.00047556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01467488,0.0007455,0.253413,0.0002343287,0.001284645,0.0006259061,0.01413785,0.00001580179,0.1334857,0.00002002431,0.2017562,0.3796062],"study_design_scores_gemma":[0.08634605,0.004252955,0.8368417,0.002006095,0.0002429289,0.001123019,0.0007534019,0.00002349687,0.002589863,0.00001137862,0.06568612,0.0001229995],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739816,0.01614206,0.000538971,0.005425537,0.0008616478,0.0002918322,0.000002679864,0.00001821166,0.002737431],"genre_scores_gemma":[0.9921718,0.001213343,0.002546509,0.0004770808,0.002396147,7.035562e-7,0.000004655465,0.00002320603,0.001166513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5834287,"threshold_uncertainty_score":0.4319869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141919552","doi":"10.1016/s0140-6736(09)61259-9","title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","year":2009,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Teva Pharmaceutical Industries; American Academy of Neurology","keywords":"Glatiramer acetate; Medicine; Multiple sclerosis; Placebo; Internal medicine; Adverse effect; Clinical endpoint; Clinically isolated syndrome; Clinical trial; Hazard ratio; Randomized controlled trial; Interim analysis; Surgery; Confidence interval; Immunology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0723496574273215,"gpt":0.3525435788101997,"spread":0.2801939213828782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006092454,0.0004243546,0.003083286,0.0002727754,0.0001267222,0.0000406304,0.0004906987,0.0001525447,0.00004524528],"category_scores_gemma":[0.004747893,0.0002220048,0.0003405248,0.0006338281,0.000158856,0.00007937766,0.0001459592,0.0007754894,0.00008777059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009051103,"about_ca_system_score_gemma":0.00009402734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005212893,"about_ca_topic_score_gemma":0.00002716867,"domain_scores_codex":[0.9944875,0.001534289,0.001573255,0.0006241374,0.001119971,0.0006608659],"domain_scores_gemma":[0.990936,0.006937231,0.0005091381,0.0010763,0.0002875438,0.0002537492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8230124,0.002423363,0.1703359,0.00004560872,0.0005078699,0.0000110917,0.0004241742,0.0001616202,0.00008524137,6.993372e-7,0.0002593167,0.002732754],"study_design_scores_gemma":[0.7046267,0.08389227,0.2100205,0.0005388893,0.0002713261,4.223172e-7,0.00002953595,0.0004171811,0.00003373517,0.000001896094,0.000007500635,0.0001600244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713071,0.00001921805,0.00001476703,0.001150809,0.0001690012,0.02693198,0.00002311453,0.00006667226,0.0003173302],"genre_scores_gemma":[0.9979779,0.00008221621,0.0002312686,0.0005921382,0.0001476781,0.0008513531,0.00002159344,0.00003626906,0.00005964116],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1183857,"threshold_uncertainty_score":0.9053091,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2800924304","doi":"10.1212/wnl.0000000000005347","title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis","year":2018,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"MedDay Pharmaceuticals","keywords":"Natalizumab; Medicine; Fingolimod; Guideline; Rituximab; Multiple sclerosis; Progressive multifocal leukoencephalopathy; Systematic review; MEDLINE; Neurology; Intensive care medicine; Family medicine; Psychiatry; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0897258710573005,"gpt":0.3628580290425424,"spread":0.2731321579852419,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003759168,0.0001955989,0.0003042464,0.0001410973,0.000385087,0.00002437961,0.0001413896,0.00007255279,0.000118352],"category_scores_gemma":[0.003935165,0.000147933,0.0000775017,0.0002080144,0.0003657664,0.0001775492,0.0001097209,0.0002373532,0.00003579856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002675297,"about_ca_system_score_gemma":0.0001050159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000194333,"about_ca_topic_score_gemma":0.0004639805,"domain_scores_codex":[0.9982429,0.0001691345,0.0003300193,0.0005065947,0.0002636507,0.0004877753],"domain_scores_gemma":[0.9967034,0.001495542,0.0001356926,0.000463135,0.0009804084,0.0002217537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1501817,0.002473401,0.1243477,0.0004637231,0.001577111,0.00006810745,0.005334344,0.00004378706,0.01891973,0.0004552056,0.4749591,0.2211761],"study_design_scores_gemma":[0.009246361,0.006454591,0.09727494,0.0001394808,0.000201592,0.00002584511,0.0003575994,0.008896388,0.0004224344,0.00004374372,0.8766966,0.000240442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.464878,0.00127995,0.01125806,0.5133471,0.0007925291,0.004773832,0.0003801885,0.0004977577,0.002792514],"genre_scores_gemma":[0.9524993,0.001226041,0.02710584,0.01746421,0.0008036771,0.0005520222,0.0001624107,0.00006134431,0.0001251413],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.495883,"threshold_uncertainty_score":0.6032534,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171100984","doi":"10.1093/brain/awq076","title":"Evidence for a two-stage disability progression in multiple sclerosis","year":2010,"lang":"en","type":"article","venue":"Brain","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple sclerosis; Expanded Disability Status Scale; Medicine; Age of onset; Disease; Proportional hazards model; Neurodegeneration; Stage (stratigraphy); Physical therapy; Pediatrics; Psychology; Internal medicine; Psychiatry; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.2623190543682773,"gpt":0.4377890418532737,"spread":0.1754699874849963,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001397572,0.0001494131,0.000296216,0.00006907741,0.0001225629,0.0000279481,0.0001539269,0.00008178626,0.0001299245],"category_scores_gemma":[0.02181769,0.0001151666,0.0001140491,0.0002452351,0.0003713589,0.0001511654,0.0001549938,0.0003633194,0.00001936188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009493341,"about_ca_system_score_gemma":0.0001005775,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002868708,"about_ca_topic_score_gemma":0.004611793,"domain_scores_codex":[0.998356,0.00008391224,0.0002897398,0.0004395997,0.0003814612,0.0004492655],"domain_scores_gemma":[0.9968015,0.002341145,0.00005639181,0.0005089369,0.0001140395,0.0001780054],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005423165,0.0003237461,0.4719487,0.000216776,0.00001053858,0.000002271404,0.0002716481,0.000001813995,0.4164966,0.00004948425,0.001277744,0.1088583],"study_design_scores_gemma":[0.004183815,0.0002198918,0.9662365,0.0007450578,0.000007481121,0.000001261849,0.0001298085,0.004461476,0.0189461,0.00002233837,0.004909521,0.0001367557],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871075,0.0001577631,0.0002236514,0.009796749,0.0001228188,0.0023424,0.00003200415,0.00007455497,0.0001425645],"genre_scores_gemma":[0.9908153,0.00003612739,0.007511033,0.0002250395,0.0001981306,0.0006721463,0.00001159747,0.00002233478,0.0005082898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4942878,"threshold_uncertainty_score":0.9864219,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077427574","doi":"10.1002/ana.21802","title":"Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica","year":2009,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":586,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research","keywords":"Neuromyelitis optica; Immunology; Aquaporin 4; Demyelinating disease; Encephalomyelitis; Antibody; Autoantibody; Antigen; Astrocyte; Medicine; Biology; Pathology; Central nervous system; Multiple sclerosis; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0961819199047716,"gpt":0.3718288439874282,"spread":0.2756469240826566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002998215,0.0001903593,0.0006349683,0.0003054751,0.0000396119,0.000008873607,0.0001751605,0.0001230098,0.00003754901],"category_scores_gemma":[0.0008512625,0.0001632799,0.0001482687,0.0002990021,0.000275894,0.00008392745,0.00008924831,0.0004420016,0.00003043524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000003411008,"about_ca_system_score_gemma":0.00004937386,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006240228,"about_ca_topic_score_gemma":0.00001344054,"domain_scores_codex":[0.9980422,0.0001842425,0.0004616044,0.0003981861,0.00030763,0.0006061533],"domain_scores_gemma":[0.9989525,0.0002438157,0.00008902393,0.000380032,0.0001883947,0.0001462332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002207535,0.001437123,0.493423,0.0001516508,0.0001492886,0.002866884,0.001193773,0.00004856634,0.4254409,0.001871505,0.003955588,0.06725422],"study_design_scores_gemma":[0.0008406412,0.003531043,0.9882743,0.00002810616,0.000009601485,0.00007259166,0.00001038887,0.0001120695,0.005239875,0.0003848306,0.001396985,0.00009952765],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9657026,0.0004894295,0.000005271319,0.03121532,0.00007897466,0.0002983737,0.00001314534,0.00003891252,0.002157964],"genre_scores_gemma":[0.9922084,0.003927037,0.000120803,0.003544661,0.0001303544,0.000007861661,0.000004961,0.00001541116,0.00004055917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4948514,"threshold_uncertainty_score":0.6658362,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133329597","doi":"10.1016/s1474-4422(13)70308-9","title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":570,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Toronto","funders":"Serono Symposia International Foundation; Universitätsspital Basel; Universität Basel","keywords":"Teriflunomide; Double blind; Multiple sclerosis; Medicine; Placebo; Internal medicine; Physical therapy; Alternative medicine; Psychiatry; Pathology; Fingolimod","retraction":null,"screen_n_in":null,"score":{"opus":0.1090696516901444,"gpt":0.3401949859973124,"spread":0.231125334307168,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001612787,0.0003426069,0.001556665,0.0001416645,0.0003781144,0.00005630185,0.0003510821,0.0001447856,0.00005382131],"category_scores_gemma":[0.002607235,0.0001915845,0.0002620372,0.0001649046,0.000377942,0.00009324794,0.0001365877,0.0005252814,0.00002220065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003276572,"about_ca_system_score_gemma":0.00006691301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004284255,"about_ca_topic_score_gemma":0.00007487942,"domain_scores_codex":[0.9970651,0.0005126095,0.0005528447,0.0005636798,0.0004144628,0.0008913557],"domain_scores_gemma":[0.9954425,0.003090634,0.0002821319,0.0007595356,0.0002490601,0.0001761972],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9836249,0.0006745658,0.004339986,0.00003719278,0.0003033448,0.000002839966,0.0001506649,0.00003632573,0.001462731,0.00002482372,0.003574903,0.005767752],"study_design_scores_gemma":[0.9724107,0.008721737,0.003082932,0.00004098257,0.0002887715,0.000005020403,0.000009005554,0.00393692,0.0001889572,0.00002701406,0.01110342,0.0001844865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9787464,0.00005811303,0.0008701081,0.007686846,0.0005364057,0.01125078,0.00004010116,0.0001234328,0.0006878383],"genre_scores_gemma":[0.9923029,0.00008386208,0.000618425,0.002414422,0.001383243,0.002911747,0.0000572947,0.00006560121,0.0001624941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01355654,"threshold_uncertainty_score":0.7812588,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2755106885","doi":"10.1016/s1474-4422(17)30278-8","title":"Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":568,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Optic neuritis; Multiple sclerosis; Retinal; Medicine; Nerve fiber layer; Ophthalmology; Meta-analysis; Optical coherence tomography; Atrophy; Optic nerve; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.568419215946183,"gpt":0.4590668017912345,"spread":0.1093524141549485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557631,0.0004401409,0.01271685,0.0003070572,0.0001672892,0.00004580095,0.0005294943,0.0001761741,0.00009879245],"category_scores_gemma":[0.00261928,0.0002155345,0.001324281,0.0004258819,0.000260203,0.00005058557,0.0003337142,0.0009028236,0.00005762499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003467004,"about_ca_system_score_gemma":0.00005952235,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000782914,"about_ca_topic_score_gemma":0.0002548038,"domain_scores_codex":[0.9951488,0.002391534,0.001013686,0.0006059415,0.0003713526,0.0004687143],"domain_scores_gemma":[0.9959791,0.001329675,0.0008659519,0.001650717,0.00009034632,0.00008425535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00003552225,0.00004100642,0.00008276443,0.9190201,0.07652991,0.00004002398,0.00005387478,4.197082e-7,0.000001023761,0.000007085965,0.0007774431,0.003410831],"study_design_scores_gemma":[0.0005301052,0.0001255267,0.0007215393,0.02374194,0.9387473,0.00009243552,0.000004645894,0.0000267036,1.903013e-7,0.00000393544,0.03581106,0.0001945969],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000008105781,0.98817,0.000003759764,0.006415587,0.00002540387,0.005137487,0.00008148126,0.00002858989,0.0001296384],"genre_scores_gemma":[0.0002093787,0.9934494,0.00005204206,0.002991692,0.00008491812,0.002886204,0.00004863195,0.00003478519,0.0002428905],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8952782,"threshold_uncertainty_score":0.8789243,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2161929126","doi":"10.1016/s1474-4422(03)00663-x","title":"Genetics of multiple sclerosis","year":2004,"lang":"en","type":"review","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":560,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Biology; Multiple sclerosis; Genetic epidemiology; Locus (genetics); Genetics; Statistical genetics; Human leukocyte antigen; Genome-wide association study; Molecular genetics; Computational biology; Gene; Genome; Evolutionary biology; Human genome; Immunology; Single-nucleotide polymorphism","retraction":null,"screen_n_in":null,"score":{"opus":0.2990294704657776,"gpt":0.3953319798797815,"spread":0.09630250941400387,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003849868,0.0003333613,0.002862974,0.0001391665,0.00007564355,0.000007071341,0.0005759147,0.0002815378,0.00005964984],"category_scores_gemma":[0.000737977,0.0001881408,0.0004516779,0.0003114739,0.0005581514,0.00001048366,0.0004193776,0.00099002,0.0001049195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003644177,"about_ca_system_score_gemma":0.0002545511,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003766107,"about_ca_topic_score_gemma":0.00001951658,"domain_scores_codex":[0.9977703,0.0003858034,0.0005592934,0.0003920922,0.0003368956,0.0005555914],"domain_scores_gemma":[0.9973706,0.000985696,0.0003066669,0.001146819,0.000102441,0.00008777162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001394697,0.0001131153,0.0003724874,0.02078341,0.0004490711,0.00002596176,0.00006743972,0.000007016742,0.00003973265,0.0000501638,0.002502964,0.9754491],"study_design_scores_gemma":[0.001145189,0.0004328999,0.003095205,0.00367282,0.0005744241,0.00007965479,0.000001903291,0.00001298326,0.0000131129,0.00002449859,0.9908164,0.0001309146],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002394496,0.9962708,0.000006963384,0.001321016,0.0002099414,0.001197863,0.00009576886,0.00005102891,0.0006071057],"genre_scores_gemma":[0.0007211536,0.9976336,0.0001766448,0.0004668653,0.0006932816,0.0001446132,0.0000293452,0.00006394813,0.00007048267],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9883134,"threshold_uncertainty_score":0.7672158,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2951680115","doi":"10.1093/brain/awz144","title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","year":2019,"lang":"en","type":"review","venue":"Brain","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":552,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Horizon 2020 Framework Programme; Sanofi Genzyme; MedDay Pharmaceuticals; Ministero della Salute; Chugai Pharmaceutical; Novartis Pharma; National Multiple Sclerosis Society; International Progressive MS Alliance; University of Oxford; National Institute of Neurological Disorders and Stroke; IXICO; Multiple Sclerosis Society; Biogen; BioClinica; Fondazione Italiana Sclerosi Multipla; Celgene; Alexion Pharmaceuticals; National Institute for Health and Care Research; Medical Research Council; Teva Pharmaceutical Industries; Deutsche Forschungsgemeinschaft; GlaxoSmithKline; Rosetrees Trust; Bayer HealthCare; Sanofi","keywords":"Multiple sclerosis; Neuromyelitis optica; Medicine; Magnetic resonance imaging; McDonald criteria; Medical diagnosis; Pathology; Radiology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.4225436994804912,"gpt":0.5045188906082448,"spread":0.08197519112775364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001416797,0.0004393518,0.002219875,0.0005414643,0.00005699313,0.00002265557,0.0002413427,0.0001849183,0.0001226105],"category_scores_gemma":[0.01303146,0.0003275044,0.0004345962,0.000544893,0.0001779071,0.00006466625,0.0003185421,0.0008618329,0.00009552976],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003351353,"about_ca_system_score_gemma":0.001064019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001158769,"about_ca_topic_score_gemma":0.00004996988,"domain_scores_codex":[0.9960555,0.0004884836,0.001292737,0.0007035147,0.0009278804,0.000531816],"domain_scores_gemma":[0.9950007,0.003331531,0.0003314756,0.0008957991,0.0002921716,0.0001483061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002145693,0.0003172232,0.001241684,0.007696817,0.00002603953,0.00003432361,0.0000184444,0.000001317628,0.00004852461,0.00009017508,0.02602905,0.9644749],"study_design_scores_gemma":[0.001358482,0.0002144029,0.0443981,0.07457579,0.0001591711,0.00001539959,0.00005300903,0.0006772337,0.000001625954,0.000002726784,0.8783044,0.0002396214],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002591833,0.9923592,0.00002479003,0.003163097,0.0001746616,0.002423734,0.00008594174,0.00003506214,0.001707588],"genre_scores_gemma":[0.0001949413,0.9898949,0.007662961,0.000359867,0.0001839964,0.0003811043,0.00005921069,0.00007862309,0.001184344],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9642353,"threshold_uncertainty_score":0.9999177,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2910867209","doi":"10.1001/jama.2018.20588","title":"Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis","year":2019,"lang":"en","type":"article","venue":"JAMA","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Notre-Dame; Université de Montréal","funders":"National Health and Medical Research Council; Debreceni Egyetem; Dokuz Eylül Üniversitesi; Università degli Studi di Firenze; Multiple Sclerosis Society; York University; Wellcome Trust; American University of Beirut; Jewish General Hospital; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Sanofi Genzyme; University of Melbourne; Medical Research Council; Biogen; NYU Langone Medical Center; NIHR Cambridge Biomedical Research Centre; Sanofi","keywords":"Medicine; Fingolimod; Glatiramer acetate; Natalizumab; Multiple sclerosis; Internal medicine; Hazard ratio; Alemtuzumab; Surgery; Disease; Confidence interval; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.0467230660719371,"gpt":0.3189398855219823,"spread":0.2722168194500452,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002344854,0.0001297899,0.0002937679,0.0001181563,0.00006322355,0.0000284318,0.00008117313,0.00007116512,0.0005217342],"category_scores_gemma":[0.0003932557,0.0000920669,0.00007445252,0.0001777273,0.00004197685,0.0001657672,0.00008333932,0.0001980024,0.000109105],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001584109,"about_ca_system_score_gemma":0.0001113781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004078095,"about_ca_topic_score_gemma":0.000006542627,"domain_scores_codex":[0.998576,0.00007079146,0.0001836291,0.0002564689,0.0006307753,0.0002822673],"domain_scores_gemma":[0.9987822,0.000238009,0.0001278245,0.0002365532,0.000434268,0.0001811614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004212237,0.0002022223,0.9220234,0.0002205368,0.0002860173,0.00001034475,0.0009973431,0.0000117765,0.04070013,0.000001749172,0.003418581,0.02791564],"study_design_scores_gemma":[0.009357638,0.0006450487,0.9515753,0.0004675147,0.00002776039,6.145518e-7,0.0002253075,0.0003408798,0.03477708,0.000001840023,0.002469092,0.0001119397],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994274,0.0001764341,0.000009005594,0.003325747,0.00008219838,0.001252462,0.00006253259,0.00003996122,0.0007776702],"genre_scores_gemma":[0.9979154,0.0001177357,0.0004689519,0.0006637745,0.0001385627,0.00007829122,0.00003771199,0.00002320581,0.0005562949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02955187,"threshold_uncertainty_score":0.5712623,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127568644","doi":"10.1002/ana.21748","title":"Preferential recruitment of interferon‐γ–expressing T<sub>H</sub>17 cells in multiple sclerosis","year":2009,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":540,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Canadian Institutes of Health Research","keywords":"Multiple sclerosis; Immunology; Experimental autoimmune encephalomyelitis; Interferon gamma; Immune system; Encephalomyelitis; Biology; Interleukin 17; In vitro; In vivo; T cell; T lymphocyte","retraction":null,"screen_n_in":null,"score":{"opus":0.3415708591831847,"gpt":0.3776409173115917,"spread":0.03607005812840702,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003333499,0.0002013543,0.0006886425,0.0003611657,0.00003812222,0.00000636896,0.0001960521,0.0001479464,0.00002726325],"category_scores_gemma":[0.0003970443,0.0001820107,0.0001640039,0.0002213692,0.0002435695,0.00008129106,0.000161602,0.0003659002,0.000007963419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001125292,"about_ca_system_score_gemma":0.00004574564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004812701,"about_ca_topic_score_gemma":0.00006287624,"domain_scores_codex":[0.9978666,0.0002346562,0.000648751,0.0003982609,0.0003459443,0.0005057578],"domain_scores_gemma":[0.9987112,0.0003022036,0.0002221804,0.0004162475,0.0002232991,0.0001248753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002212375,0.0007364085,0.005554357,0.00007619368,0.00005657228,0.00001108967,0.0003021116,0.0001062953,0.9564289,0.000008638125,0.002716622,0.03179042],"study_design_scores_gemma":[0.001537259,0.002733437,0.2952993,0.0001645832,0.00001438364,0.00000263076,0.00001737019,0.0004362264,0.6992692,0.00003998957,0.0004059804,0.00007958269],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947219,0.0003099216,0.00003143934,0.003552081,0.0001111109,0.0007436892,0.00002450028,0.00002432904,0.0004809779],"genre_scores_gemma":[0.9965109,0.002010405,0.0001104102,0.001215728,0.00007139828,0.00003972312,0.000009478762,0.00001741761,0.00001449971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2897449,"threshold_uncertainty_score":0.742218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}